Literature DB >> 28440331

Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

Paul Lorigan1, Adele C Green2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28440331     DOI: 10.1038/nrclinonc.2017.60

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

Review 1.  Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.

Authors:  Alexander C J van Akkooi; Michael B Atkins; Sanjiv S Agarwala; Paul Lorigan
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Authors:  Sanjiv S Agarwala; Sandra J Lee; Waiki Yip; Uma N Rao; Ahmad A Tarhini; Gary I Cohen; Douglas S Reintgen; Terry L Evans; Joanna M Brell; Mark R Albertini; Michael B Atkins; Shaker R Dakhil; Robert M Conry; Jeffrey A Sosman; Lawrence E Flaherty; Vernon K Sondak; William E Carson; Michael G Smylie; Alberto S Pappo; Richard F Kefford; John M Kirkwood
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

4.  Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Authors:  Corneel Coens; Stefan Suciu; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Celeste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Andrew Bottomley; Srividya Kotapati; Veerle de Pril; Alessandro Testori; Alexander M M Eggermont
Journal:  Lancet Oncol       Date:  2017-02-03       Impact factor: 41.316

Review 5.  Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.

Authors:  Matthew Howell; Rebecca Lee; Samantha Bowyer; Alberto Fusi; Paul Lorigan
Journal:  Lung Cancer       Date:  2015-02-16       Impact factor: 5.705

6.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

7.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

  7 in total
  2 in total

1.  Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.

Authors:  M Bloemendal; M J A Rietveld; W W van Willigen; W R Gerritsen; C G Figdor; J J Bonenkamp; H Westdorp; S Boudewijns; R H T Koornstra; E M M Adang; G Schreibelt; P B Ottevanger; I J M de Vries; K F Bol
Journal:  Clin Transl Oncol       Date:  2018-11-21       Impact factor: 3.405

2.  Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.

Authors:  Helen M McGuire; Elena Shklovskaya; Jarem Edwards; Paul R Trevillian; Geoffrey W McCaughan; Patrick Bertolino; Catriona McKenzie; Ralph Gourlay; Stuart J Gallagher; Barbara Fazekas de St Groth; Peter Hersey
Journal:  Cancer Immunol Immunother       Date:  2017-12-30       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.